Latest Derivatives News

Alkane Resources reports its Q1 FY2026 interim results, highlighting the integration of Mandalay Resources and key operational developments across its global mining portfolio.

Navigator Global Investments (NGI) reveals a robust business model focused on minority stakes in alternative asset managers, supported by strategic partnerships and a diversified portfolio. The company targets doubling its EBITDA by 2030 amid strong industry tailwinds.

BPH Global Ltd is pioneering a novel seaweed-based natural formulation targeting male vitality, staking a first-mover claim in this emerging segment of men’s health. The company’s R&D, led by Gaia Mariculture, aims to launch an OTC supplement with potential for clinical validation.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

NexGen Energy Ltd. reported a significant net loss for the nine months ended September 30, 2025, driven by mark-to-market losses on convertible debentures and impairment charges. The company bolstered its liquidity with a $953 million equity raise post-period.

Perpetual Credit Income Trust (PCI) has announced a $267 million entitlement and shortfall offer priced at $1.10 per unit, aiming to bolster its investment capacity in Australian credit markets. The offer presents a 9.1% discount to recent trading prices and is designed to enhance liquidity and scale for existing and new investors.

Macquarie Group reported a 3% rise in net profit to A$1.655 billion for the half year ended September 2025, driven by strong growth in asset management and capital divisions. The group also extended its A$2 billion share buyback program and declared a solid interim dividend.

Macquarie Group Limited has announced a quarterly distribution of AUD 1.5799 per security on its perpetual capital notes, reflecting a steady income stream with partial franking. The payment is scheduled for December 12, 2025.

Macquarie Group Limited announces a quarterly dividend of AUD 1.4003 per security on its CAP NOTE 3-BBSW+2.90% PERP NON-CUM RED T-09-27, with a partly franked distribution and a payment date set for December 18, 2025.

Macquarie Group Limited has announced a quarterly distribution of AUD 1.6773 per security for its capital note, payable on December 10, 2025, reflecting a stable income stream for investors.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.